This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), is for the development of an antibody-oligonucleotide conjugate (MC-30) for the treatment of head and neck squamous cell carcinoma (HNSCC). Mirecule, Inc., a small disadvantaged business, will receive $863,708 over the 2-year period from September 2024 to August 2026 to validate the efficacy of MC-30 in preclinical models, scale up the manufacturing process, and conduct toxicology studies to support an Investigational New Drug (IND) application with the FDA. The proposed MC-30 conjugate combines the anti-EGFR antibody cetuximab with a chemically modified mimic of the tumor suppressor microRNA miR-30-5p, which has the potential to simultaneously target and repress multiple oncogenic signaling pathways in HNSCC. Successful execution of this project is expected to complete the data package for the pre-IND meeting and enable the initiation of IND-enabling studies for this novel cancer therapy.
Generated 3/25/25, 5:03 AM